3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Conditions
Breast Neoplasms
3
Sarcoma
2
Triple Negative Breast Neoplasms
1
Sarcoma, Ewing
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplasm Metastasis
1
Her-2 Negative Breast Cancer
1
Fludzoparib" and Anti-angiogenic
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Breast Cancer Metastatic
1
Advanced Solid Tumors
1
Interventions
Doxorubicin
15
pembrolizumab
12
Surgical Procedures, Operative
8
Cyclophosphamide
8
Blood Specimen Collection
8
Ifosfamide
7
Gemcitabine
7
Surveys and Questionnaires
6
Nivolumab
6
Trabectedin
5
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Drug Therapy
5
atezolizumab
4
Temozolomide
4
Specimen Handling
4
Radiation Dose Hypofractionation
4
Biopsy
4
pazopanib
3
liposomal doxorubicin
3
fludarabine
3
cabozantinib
3
anlotinib
3
Radiation
3
Observation
3
Docetaxel
3
Dacarbazine
3
trastuzumab deruxtecan
2
toripalimab
2
selinexor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Sarcoma
×
fluzoparib
×
Clear all
NCT05894018
2025-05-13
RAFAS-001
Sun Yat-sen University
Phase 2
Recruiting
32 enrolled
NCT06074692
2023-10-31
PRIMA
Ruijin Hospital
Phase 2
Recruiting
86 enrolled